BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011;79:158-162. [PMID: 20399035 DOI: 10.1016/j.ijrobp.2009.10.043] [Cited by in Crossref: 101] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis]
Number Citing Articles
1 Hasumi K, Aoki Y, Wantanabe R, Mann DL. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology 2013;2:e26381. [PMID: 24349874 DOI: 10.4161/onci.26381] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
2 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
3 Buwenge M, Marinelli A, Deodato F, Macchia G, Wondemagegnhu T, Salah T, Cammelli S, Uddin AFMK, Sumon MA, Donati CM, Cilla S, Morganti AG. Definition of fields margins for palliative radiotherapy of pancreatic carcinoma. Mol Clin Oncol 2018;8:715-8. [PMID: 29844901 DOI: 10.3892/mco.2018.1605] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Trakul N, Koong AC, Maxim PG, Chang DT. Modern radiation therapy techniques for pancreatic cancer. Gastroenterol Clin North Am 2012;41:223-35. [PMID: 22341260 DOI: 10.1016/j.gtc.2011.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
5 Hasumi K, Aoki Y, Watanabe R, Hankey KG, Mann DL. Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy. Cancers (Basel) 2011;3:2223-42. [PMID: 24212806 DOI: 10.3390/cancers3022223] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Sbeit W, Napoléon B, Khoury T. Endoscopic ultrasound role in pancreatic adenocarcinoma treatment: A review focusing on technical success, safety and efficacy. World J Gastroenterol 2022; 28(3): 332-347 [DOI: 10.3748/wjg.v28.i3.332] [Reference Citation Analysis]
7 Huguet F, Rivin Del Campo E, Orthuon A, Mornex F, Bessières I, Guimas V, Vendrely V. Radiation therapy of pancreatic cancers. Cancer Radiother 2021:S1278-3218(21)00199-2. [PMID: 34953706 DOI: 10.1016/j.canrad.2021.08.010] [Reference Citation Analysis]
8 Figl M, Kaar M, Hoffman R, Kratochwil A, Hummel J. An error analysis perspective for patient alignment systems. Int J Comput Assist Radiol Surg 2013;8:849-56. [PMID: 23463386 DOI: 10.1007/s11548-013-0819-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Bittner M, Grosu A, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer – A systematic review. Radiotherapy and Oncology 2015;114:117-21. [DOI: 10.1016/j.radonc.2014.11.043] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
10 Weltman E, Marta G, Baraldi H, Pimentel L, Castilho M, Maia M, Lundgren M, Chen M, Novaes P, Gadia R, Ferrigno R, Motta R, Hanna S, Almeida W. Treatment of abdominal tumors using radiotherapy. Rev Assoc Med Bras 2015;61:108-13. [DOI: 10.1590/1806-9282.61.02.108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Kim BH, Chie EK, Kim K, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW. Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. Oncotarget 2017;8:78076-85. [PMID: 29100449 DOI: 10.18632/oncotarget.17368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 2012;82:e595-601. [DOI: 10.1016/j.ijrobp.2011.09.035] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
13 Kucuktulu E, Yurekli AF, Topbas M, Kece C, Guner A, Kucuktulu U. Comparisons between the Dosimetric and Clinical Outcomes of Tomotherapy and 3D Conformal Radiotherapy in Gastric Cancer Treatment. Asian Pac J Cancer Prev 2019;20:595-9. [PMID: 30806065 DOI: 10.31557/APJCP.2019.20.2.595] [Reference Citation Analysis]
14 Buwenge M, Cellini F, Silvestris N, Cilla S, Deodato F, Macchia G, Mattiucci GC, Valentini V, Morganti AG. Robotic radiosurgery in pancreatic cancer: A systematic review. World J Gastroenterol 2015; 21(31): 9420-9429 [PMID: 26309369 DOI: 10.3748/wjg.v21.i31.9420] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
15 Diener MK, Combs SE, Büchler MW. Chemoradiotherapy for locally advanced pancreatic cancer. Lancet Oncol 2013;14:269-70. [PMID: 23474364 DOI: 10.1016/S1470-2045(13)70091-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
16 Jin L, Wang R, Jiang S, Yue J, Liu T, Dou X, Zhu K, Feng R, Xu X, Chen D, Yin Y. Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head. Curr Oncol 2016;23:e41-8. [PMID: 26966412 DOI: 10.3747/co.23.2771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Xu KM, Rajagopalan MS, Kim H, Beriwal S. Extended field intensity modulated radiation therapy for gynecologic cancers: Is the risk of duodenal toxicity high? Practical Radiation Oncology 2015;5:e291-7. [DOI: 10.1016/j.prro.2014.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
18 Bahl A, Bhattacharyya T, Kapoor R, Singh OA, Parsee T, Sharma SC. Postoperative radiotherapy in periampullary cancers: a brief review. J Gastrointest Cancer 2013;44:111-4. [PMID: 22843209 DOI: 10.1007/s12029-012-9421-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Gurney-champion OJ, Versteijne E, van der Horst A, Lens E, Rütten H, Heerkens HD, Paardekooper GMRM, Berbee M, Rasch CRN, Stoker J, Engelbrecht MRW, van Herk M, Nederveen AJ, Klaassen R, van Laarhoven HWM, van Tienhoven G, Bel A. Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. Acta Oncologica 2017;56:923-30. [DOI: 10.1080/0284186x.2017.1304654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Lim YJ, Kim K. Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma: a propensity score-adjusted analysis of Surveillance, Epidemiology, and End Results database. Int J Clin Oncol 2018;23:473-81. [DOI: 10.1007/s10147-017-1226-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Lee KJ, Yoon HI, Chung MJ, Park JY, Bang S, Park SW, Seong JS, Song SY. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Gut Liver 2016;10:303-9. [PMID: 26470767 DOI: 10.5009/gnl15186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
22 Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010;7:437-447. [PMID: 20628346 DOI: 10.1038/nrgastro.2010.98] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
23 Chang JS, Wang ML, Koom WS, Yoon HI, Chung Y, Song SY, Seong J. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;83:1448-54. [PMID: 22285669 DOI: 10.1016/j.ijrobp.2011.10.050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ding X, Dionisi F, Tang S, Ingram M, Hung CY, Prionas E, Lichtenwalner P, Butterwick I, Zhai H, Yin L. A comprehensive dosimetric study of pancreatic cancer treatment using three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT), and passive-scattering and modulated-scanning proton therapy (PT). Med Dosim. 2014;39:139-145. [PMID: 24661778 DOI: 10.1016/j.meddos.2013.11.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
25 Prasad S, Cambridge L, Huguet F, Chou JF, Zhang Z, Wu AJ, O'Reilly EM, Allen PJ, Goodman KA. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. Pract Radiat Oncol 2016;6:78-85. [PMID: 26577010 DOI: 10.1016/j.prro.2015.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
26 Kennoki N, Nakayama H, Nagakawa Y, Hosokawa Y, Itonaga T, Tajima YU, Shiraishi S, Mikami R, Tsuchida A, Tokuuye K. Feasibility of intensity-modulated radiotherapy combined with gemcitabine and S-1 for patients with pancreatic cancer. Mol Clin Oncol 2016;4:43-6. [PMID: 26870355 DOI: 10.3892/mco.2015.664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Goodman KA, Hajj C. Role of radiation therapy in the management of pancreatic cancer. J Surg Oncol. 2013;107:86-96. [PMID: 22532174 DOI: 10.1002/jso.23137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
28 Nabavizadeh N, Simeonova AO, Waller JG, Romer JL, Monaco DL, Elliott DA, Tanyi JA, Fuss M, Thomas CR Jr, Holland JM. Volumetric-modulated arc radiotherapy for pancreatic malignancies: dosimetric comparison with sliding-window intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Med Dosim 2014;39:256-60. [PMID: 24857696 DOI: 10.1016/j.meddos.2014.04.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
29 Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, Kim HM, Park SW. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemother Pharmacol. 2016;78:841-846. [PMID: 27586966 DOI: 10.1007/s00280-016-3143-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dalwadi SM, Herman JM, Das P, Holliday EB. Novel Radiotherapy Technologies in the Treatment of Gastrointestinal Malignancies. Hematol Oncol Clin North Am 2020;34:29-43. [PMID: 31739949 DOI: 10.1016/j.hoc.2019.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Hajj C, Goodman KA. Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. JCO 2015;33:1737-44. [DOI: 10.1200/jco.2014.59.9787] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
32 Lee HC, Lee JH, Lee SW, Lee JH, Yu M, Jang HS, Kim SH. Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer. Radiat Oncol J 2019;37:279-85. [PMID: 31918466 DOI: 10.3857/roj.2019.00430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Huguet F, Mornex F, Orthuon A. [Radiation therapy of pancreatic cancer]. Cancer Radiother 2016;20 Suppl:S169-73. [PMID: 27523418 DOI: 10.1016/j.canrad.2016.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
35 Nakamura A, Shibuya K, Nakamura M, Matsuo Y, Shiinoki T, Nakata M, Mizowaki T, Hiraoka M. Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy. Med Phys 2013;40:021701. [PMID: 23387724 DOI: 10.1118/1.4773033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
36 Tseng YD, Wo JY, Ancukiewicz M, Adams J, Depauw N, Mamon HJ, Hong TS. Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer. J Radiat Oncol 2013;2:427-34. [DOI: 10.1007/s13566-013-0114-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Nichols RC, George TJ, Zaiden RA, Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncologica 2013;52:498-505. [DOI: 10.3109/0284186x.2012.762997] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
38 Oh ES, Kim TH, Woo SM, Lee WJ, Lee JH, Youn SH, Han SS, Park SJ, Kim DY. Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer. Radiat Oncol J 2018;36:200-9. [DOI: 10.3857/roj.2018.00073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Dreher C, Habermehl D, Ecker S, Brons S, El-Shafie R, Jäkel O, Debus J, Combs SE. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiat Oncol 2015;10:237. [PMID: 26590103 DOI: 10.1186/s13014-015-0538-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
40 Thompson RF, Mayekar SU, Zhai H, Both S, Apisarnthanarax S, Metz JM, Plastaras JP, Ben-Josef E. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41:081711. [PMID: 25086521 DOI: 10.1118/1.4887797] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
41 Bohoudi O, Bruynzeel AME, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Palacios MA. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother Oncol. 2017;125:439-444. [PMID: 28811038 DOI: 10.1016/j.radonc.2017.07.028] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 26.8] [Reference Citation Analysis]
42 Kelly P, Das P, Varadhachary GR, Fontanilla HP, Krishnan S, Delclos ME, Jhingran A, Eifel PJ, Crane CH. Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis. Int J Radiat Oncol Biol Phys 2012;82:2012-7. [PMID: 21640510 DOI: 10.1016/j.ijrobp.2011.03.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Chavalitdhamrong D, DiMaio CJ, Siersema PD, Wagh MS. Technical advances in endoscopic ultrasound-guided fiducial placement for the treatment of pancreatic cancer. Endosc Int Open 2015;3:E373-7. [PMID: 26355267 DOI: 10.1055/s-0034-1392274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
44 Dai ZT, Ma L, Cao TT, Zhu L, Zhao M, Li N. Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer. Sci Rep 2021;11:4065. [PMID: 33603030 DOI: 10.1038/s41598-021-83648-5] [Reference Citation Analysis]
45 Nakamura M, Shibuya K, Nakamura A, Shiinoki T, Matsuo Y, Nakata M, Sawada A, Mizowaki T, Hiraoka M. Interfractional dose variations in intensity-modulated radiotherapy with breath-hold for pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;82:1619-26. [PMID: 21477941 DOI: 10.1016/j.ijrobp.2011.01.050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
46 Reese AS, Lu W, Regine WF. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Semin Radiat Oncol 2014;24:132-9. [PMID: 24635870 DOI: 10.1016/j.semradonc.2013.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
47 Nour AA, Alaradi A, Mohamed A, Altuwaijri S, Rudat V. Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity. Radiat Oncol 2013;8:207. [PMID: 24007346 DOI: 10.1186/1748-717X-8-207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
48 Ling TC, Slater JM, Mifflin R, Nookala P, Grove R, Ly AM, Patyal B, Slater JD, Yang GY. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848. J Gastrointest Oncol 2015;6:108-14. [PMID: 25830030 DOI: 10.3978/j.issn.2078-6891.2014.094] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
49 Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Goodman KA, Jabbour SK, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; Expert Panel on Radiation OncologyGastrointestinal. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Am J Clin Oncol 2017;40:109-17. [PMID: 28230650 DOI: 10.1097/COC.0000000000000370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 2018;41:59-64. [PMID: 26325492 DOI: 10.1097/COC.0000000000000227] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol 2020;11:166-75. [PMID: 32175120 DOI: 10.21037/jgo.2019.03.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
52 Grimbergen G, Eijkelenkamp H, Heerkens HD, Raaymakers BW, Intven MPW, Meijer GJ. Intrafraction pancreatic tumor motion patterns during ungated magnetic resonance guided radiotherapy with an abdominal corset. Phys Imaging Radiat Oncol 2022;21:1-5. [PMID: 35005257 DOI: 10.1016/j.phro.2021.12.001] [Reference Citation Analysis]
53 Li YF, Liu ZQ, Zhang YS, Dong LM, Wang CY, Gou SM, Wu HS. Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. J Huazhong Univ Sci Technolog Med Sci 2016;36:205-10. [PMID: 27072963 DOI: 10.1007/s11596-016-1567-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
54 Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:741-59. [PMID: 26226908 DOI: 10.1016/j.hoc.2015.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
55 Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, Tuli R, Laheru DA, Wolfgang CL, Diaz LA Jr, Herman JM. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract Radiat Oncol 2012;2:77-85. [PMID: 23585823 DOI: 10.1016/j.prro.2011.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
56 Sasaki M, Nakamura M, Mukumoto N, Goto Y, Ishihara Y, Nakata M, Sugimoto N, Mizowaki T. Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases. J Appl Clin Med Phys 2019;20:118-26. [PMID: 31539194 DOI: 10.1002/acm2.12720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013;14:293-310. [PMID: 23793524 DOI: 10.1007/s11864-013-0244-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
58 Raturi VP, Tochinai T, Hojo H, Rachi T, Hotta K, Nakamura N, Zenda S, Motegi A, Ariji T, Hirano Y, Baba H, Ohyoshi H, Nakamura M, Okumura M, Bei Y, Akimoto T. Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis. Front Oncol 2020;10:517061. [PMID: 33194580 DOI: 10.3389/fonc.2020.517061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Soares I, Dias J, Rocha H, Khouri L, do Carmo Lopes M, Ferreira B. Predicting xerostomia after IMRT treatments: a data mining approach. Health Technol 2018;8:159-68. [DOI: 10.1007/s12553-017-0204-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Chapman KL, Witek ME, Chen H, Showalter TN, Bar-Ad V, Harrison AS. Pancreatic cancer planning: Complex conformal vs modulated therapies. Med Dosim 2016;41:100-4. [PMID: 26831922 DOI: 10.1016/j.meddos.2015.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
61 Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jäger D, Büchler MW, Debus J. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 2013;189:738-44. [PMID: 23896630 DOI: 10.1007/s00066-013-0391-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
62 Chan RW, Podgorsak MB. Ipsilateral kidney sparing in treatment of pancreatic malignancies using volumetric-modulated arc therapy avoidance sectors. Med Dosim 2015;40:175-80. [PMID: 25524821 DOI: 10.1016/j.meddos.2014.10.006] [Reference Citation Analysis]
63 Wu JM, Yu TJ, Yeh SA, Chao PJ, Huang CJ, Lee TF. Use dose bricks concept to implement nasopharyngeal carcinoma treatment planning. Biomed Res Int 2014;2014:720876. [PMID: 24967395 DOI: 10.1155/2014/720876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Erdek MA, King LM, Ellsworth SG. Pain management and palliative care in pancreatic cancer. Curr Probl Cancer. 2013;37:266-272. [PMID: 24331181 DOI: 10.1016/j.currproblcancer.2013.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
65 Koom WS, Mori S, Furuich W, Yamada S. Beam direction arrangement using a superconducting rotating gantry in carbon ion treatment for pancreatic cancer. Br J Radiol 2019;92:20190101. [PMID: 30943057 DOI: 10.1259/bjr.20190101] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Hong TS, Wo JY, Kwak EL. A matter of timing: is there a role for radiation in locally advanced pancreatic cancer, and if so, when? Am Soc Clin Oncol Educ Book 2012;:238-42. [PMID: 24451741 DOI: 10.14694/EdBook_AM.2012.32.14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Larghi A, Rimbaș M, Rizzatti G, Carbone C, Gasbarrini A, Costamagna G, Alfieri S, Tortora G. Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. Semin Oncol 2021:S0093-7754(21)00004-X. [PMID: 33608132 DOI: 10.1053/j.seminoncol.2021.01.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Vieillot S, Azria D, Riou O, Moscardo CL, Dubois JB, Aillères N, Fenoglietto P. Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol 2011;6:147. [PMID: 22040762 DOI: 10.1186/1748-717X-6-147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012;83:1120-1125. [PMID: 22099048 DOI: 10.1016/j.ijrobp.2011.09.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
70 Kubo K, Wadasaki K, Komichi D, Sasaki T, Yamada H, Matsugu Y, Itamoto T, Doi M, Shinozaki K. A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy. PLoS One 2019;14:e0227305. [PMID: 31887205 DOI: 10.1371/journal.pone.0227305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Cho I, Park JW, Cho B, Kwak J, Yoon SM, Nesseler JP, Park J, Kim JH. Dosimetric analysis of stereotactic rotational versus static intensity-modulated radiation therapy for pancreatic cancer. Cancer Radiother 2018;22:754-62. [PMID: 30322818 DOI: 10.1016/j.canrad.2018.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Yovino S, Maidment BW 3rd, Herman JM, Pandya N, Goloubeva O, Wolfgang C, Schulick R, Laheru D, Hanna N, Alexander R, Regine WF. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012;83:916-20. [PMID: 22284684 DOI: 10.1016/j.ijrobp.2011.08.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
73 Chang DS, Bartlett GK, Das IJ, Cardenes HR. Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary? Clin Transl Oncol 2013;15:720-4. [PMID: 23359183 DOI: 10.1007/s12094-012-0998-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
74 Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol. 2011;2:157-167. [PMID: 22811846 DOI: 10.3978/j.issn.2078-6891.2011.032] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
75 Cattaneo GM, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, di Muzio N, Calandrino R. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiotherapy and Oncology 2013;108:66-71. [DOI: 10.1016/j.radonc.2013.05.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
76 Colbert LE, Moningi S, Chadha A, Amer A, Lee Y, Wolff RA, Varadhachary G, Fleming J, Katz M, Das P, Krishnan S, Koay EJ, Park P, Crane CH, Taniguchi CM. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol 2017;2:403-15. [PMID: 29114609 DOI: 10.1016/j.adro.2017.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
77 Chuong MD, Springett GM, Weber J, Klapman J, Vignesh S, Hodul PJ, Malafa MP, Leuthold S, Hoffe SE, Shridhar R. Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer. J Radiat Oncol 2012;1:273-81. [DOI: 10.1007/s13566-012-0039-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
78 Goodman KA, Regine WF, Dawson LA, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys 2012;83:901-8. [PMID: 22483737 DOI: 10.1016/j.ijrobp.2012.01.022] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
79 Goto Y, Nakamura A, Ashida R, Sakanaka K, Itasaka S, Shibuya K, Matsumoto S, Kanai M, Isoda H, Masui T, Kodama Y, Takaori K, Hiraoka M, Mizowaki T. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Radiat Oncol 2018;13:118. [PMID: 29940984 DOI: 10.1186/s13014-018-1063-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
80 Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol 2014;113:41-6. [PMID: 25443499 DOI: 10.1016/j.radonc.2014.09.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
81 Jabbour SK, Mulvihill D. Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol. 2014;24:85-93. [PMID: 24635865 DOI: 10.1016/j.semradonc.2013.11.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
82 Ng SP, Koay EJ. Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Ann Pancreat Cancer 2018;1:22. [PMID: 30198024 DOI: 10.21037/apc.2018.07.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Lancellotta V, Russo G, Lupattelli M, Iacco M, Perrucci E, Zucchetti C, Falcinelli L, Aristei C. Helical tomotherapy for duodenal adenocarcinoma in an elderly patient: A case report. World J Gastrointest Oncol 2017; 9(2): 94-97 [PMID: 28255431 DOI: 10.4251/wjgo.v9.i2.94] [Reference Citation Analysis]
84 Caravatta L, Macchia G, Mattiucci GC, Sainato A, Cernusco NL, Mantello G, Di Tommaso M, Trignani M, De Paoli A, Boz G, Friso ML, Fusco V, Di Nicola M, Morganti AG, Genovesi D. Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience. Radiat Oncol 2014;9:198. [PMID: 25199768 DOI: 10.1186/1748-717X-9-198] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
85 Huguet F, Dabout V, Rivin Del Campo E, Gaujoux S, Bachet JB. The role of radiotherapy in locally advanced pancreatic cancer. Br J Radiol 2021;94:20210044. [PMID: 34374297 DOI: 10.1259/bjr.20210044] [Reference Citation Analysis]
86 Woo SM, Kim MK, Joo J, Yoon KA, Park B, Park SJ, Han SS, Lee JH, Hong EK, Kim YH, Moon H, Kong SY, Kim TH, Lee WJ. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. Cancer Res Treat 2017;49:1022-32. [PMID: 28111423 DOI: 10.4143/crt.2016.495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
87 Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, Schefter T, Goodman KA. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Pancreas 2017;46:904-12. [PMID: 28697131 DOI: 10.1097/MPA.0000000000000876] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
88 Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol. 2013;8:44. [PMID: 23452509 DOI: 10.1186/1748-717X-8-44] [Cited by in Crossref: 72] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
89 Takakura T, Nakamura M, Shibuya K, Nakata M, Nakamura A, Matsuo Y, Shiinoki T, Higashimura K, Teshima T, Hiraoka M. Effects of interportal error on dose distribution in patients undergoing breath-holding intensity-modulated radiotherapy for pancreatic cancer: evaluation of a new treatment planning method. J Appl Clin Med Phys 2013;14:43-51. [PMID: 24036858 DOI: 10.1120/jacmp.v14i5.4252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Chuong MD, Boggs DH, Patel KN, Regine WF. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol. 2014;5:166-177. [PMID: 24982765 DOI: 10.3978/j.issn.2078-6891.2014.025] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
91 Huguet F, Hajj C, Winston CB, Shi W, Zhang Z, Wu AJ, O'Reilly EM, Reidy DL, Allen P, Goodman KA. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Acta Oncol 2017;56:384-90. [PMID: 27796165 DOI: 10.1080/0284186X.2016.1245862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
92 Xi M, Zhang L, Li QQ, Zhao L, Zhang R, Liu MZ. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys 2013;14:4162. [PMID: 23652248 DOI: 10.1120/jacmp.v14i3.4162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, Shibuya K, Kanai M, Masui T, Fukuda A, Isoda H, Hiraoka M, Mizowaki T. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiat Oncol 2020;15:264. [PMID: 33187523 DOI: 10.1186/s13014-020-01712-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Shridhar R, Chuong MD, Weber J, Freilich J, Almhanna K, Coppola D, Dinwoodie W, Dilling TJ, Fernandez D, Karl RC, Meredith KL, Hoffe SE. Outcomes of definitive or preoperative IMRT chemoradiation for esophageal cancer. J Radiat Oncol 2012;1:347-54. [DOI: 10.1007/s13566-012-0048-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]